Selected research
Market Outlook & Growth Opportunities
Global Autoimmune Disease Drug Market Outlook and Growth Opportunities 2026
Market perspective
The global Autoimmune Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Autoimmune Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Autoimmune Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Autoimmune Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Autoimmune Disease Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Autoimmune Disease Drug market include Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Amgen, AbbVie, Bristol-Myers Squibb, Biogen and AstraZeneca plc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Autoimmune Disease Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Autoimmune Disease Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Autoimmune Disease Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Autoimmune Disease Drug market.
Autoimmune Disease Drug Segment by Company
Roche
Eli Lilly
Pfizer
GlaxoSmithKline
Amgen
AbbVie
Bristol-Myers Squibb
Biogen
AstraZeneca plc
Abbott Laboratories
Autoimmune Disease Drug Segment by Type
NSAIDs
Interferons
Antihyperglycemics
Anti-Inflammatory
Others
Autoimmune Disease Drug Segment by Application
Psoriasis
Inflammatory Bowel Disease
Rheumatoid Arthritis
Lupus
Multiple Sclerosis
Type 1 Diabetes
Others
Autoimmune Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Autoimmune Disease Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Autoimmune Disease Drug key companies, revenue, market share, and recent developments.
3. To split the Autoimmune Disease Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Autoimmune Disease Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Autoimmune Disease Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Autoimmune Disease Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autoimmune Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Autoimmune Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autoimmune Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Autoimmune Disease Drug industry.
Chapter 3: Detailed analysis of Autoimmune Disease Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Autoimmune Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Autoimmune Disease Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Autoimmune Disease Drug Industry Trends
Table 2. Autoimmune Disease Drug Industry Drivers
Table 3. Autoimmune Disease Drug Industry Opportunities and Challenges
Table 4. Autoimmune Disease Drug Industry Restraints
Table 5. Global Autoimmune Disease Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Autoimmune Disease Drug Revenue Share by Company (2021-2026)
Table 7. Global Autoimmune Disease Drug Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Autoimmune Disease Drug Key Company Manufacturing Base & Headquarters
Table 9. Global Autoimmune Disease Drug Company, Product Type & Application
Table 10. Global Autoimmune Disease Drug Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Autoimmune Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of NSAIDs
Table 15. Significant Companies of Interferons
Table 16. Significant Companies of Antihyperglycemics
Table 17. Significant Companies of Anti-Inflammatory
Table 18. Significant Companies of Others
Table 19. Global Autoimmune Disease Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 20. Global Autoimmune Disease Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 21. Global Autoimmune Disease Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 22. Global Autoimmune Disease Drug Sales Value Share by Type (2021-2026)
Table 23. Global Autoimmune Disease Drug Sales Value Share by Type (2027-2032)
Table 24. Significant Companies of Psoriasis
Table 25. Significant Companies of Inflammatory Bowel Disease
Table 26. Significant Companies of Rheumatoid Arthritis
Table 27. Significant Companies of Lupus
Table 28. Significant Companies of Multiple Sclerosis
Table 29. Significant Companies of Type 1 Diabetes
Table 30. Significant Companies of Others
Table 31. Global Autoimmune Disease Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Autoimmune Disease Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 33. Global Autoimmune Disease Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 34. Global Autoimmune Disease Drug Sales Value Share by Application (2021-2026)
Table 35. Global Autoimmune Disease Drug Sales Value Share by Application (2027-2032)
Table 36. Global Autoimmune Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global Autoimmune Disease Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 38. Global Autoimmune Disease Drug Sales Value Share by Region (2021-2026)
Table 39. Global Autoimmune Disease Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 40. Global Autoimmune Disease Drug Sales Value Share by Region (2027-2032)
Table 41. Global Autoimmune Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 42. Global Autoimmune Disease Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 43. Global Autoimmune Disease Drug Sales Value Market Share by Country (2021-2026)
Table 44. Global Autoimmune Disease Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 45. Global Autoimmune Disease Drug Sales Value Market Share by Country (2027-2032)
Table 46. Roche Company Information
Table 47. Roche Business Overview
Table 48. Roche Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 49. Roche Autoimmune Disease Drug Product Portfolio
Table 50. Roche Recent Development
Table 51. Eli Lilly Company Information
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 54. Eli Lilly Autoimmune Disease Drug Product Portfolio
Table 55. Eli Lilly Recent Development
Table 56. Pfizer Company Information
Table 57. Pfizer Business Overview
Table 58. Pfizer Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Pfizer Autoimmune Disease Drug Product Portfolio
Table 60. Pfizer Recent Development
Table 61. GlaxoSmithKline Company Information
Table 62. GlaxoSmithKline Business Overview
Table 63. GlaxoSmithKline Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 64. GlaxoSmithKline Autoimmune Disease Drug Product Portfolio
Table 65. GlaxoSmithKline Recent Development
Table 66. Amgen Company Information
Table 67. Amgen Business Overview
Table 68. Amgen Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. Amgen Autoimmune Disease Drug Product Portfolio
Table 70. Amgen Recent Development
Table 71. AbbVie Company Information
Table 72. AbbVie Business Overview
Table 73. AbbVie Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. AbbVie Autoimmune Disease Drug Product Portfolio
Table 75. AbbVie Recent Development
Table 76. Bristol-Myers Squibb Company Information
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 79. Bristol-Myers Squibb Autoimmune Disease Drug Product Portfolio
Table 80. Bristol-Myers Squibb Recent Development
Table 81. Biogen Company Information
Table 82. Biogen Business Overview
Table 83. Biogen Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 84. Biogen Autoimmune Disease Drug Product Portfolio
Table 85. Biogen Recent Development
Table 86. AstraZeneca plc Company Information
Table 87. AstraZeneca plc Business Overview
Table 88. AstraZeneca plc Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. AstraZeneca plc Autoimmune Disease Drug Product Portfolio
Table 90. AstraZeneca plc Recent Development
Table 91. Abbott Laboratories Company Information
Table 92. Abbott Laboratories Business Overview
Table 93. Abbott Laboratories Autoimmune Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Abbott Laboratories Autoimmune Disease Drug Product Portfolio
Table 95. Abbott Laboratories Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Authors List of This Report
Table 98. Secondary Sources
Table 99. Primary Sources
List of Figures
Figure 1. Autoimmune Disease Drug Product Image
Figure 2. Global Autoimmune Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Autoimmune Disease Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Autoimmune Disease Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. NSAIDs Image
Figure 8. Interferons Image
Figure 9. Antihyperglycemics Image
Figure 10. Anti-Inflammatory Image
Figure 11. Others Image
Figure 12. Global Autoimmune Disease Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 13. Global Autoimmune Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 14. Global Autoimmune Disease Drug Sales Value Share by Type (2021-2032)
Figure 15. Psoriasis Image
Figure 16. Inflammatory Bowel Disease Image
Figure 17. Rheumatoid Arthritis Image
Figure 18. Lupus Image
Figure 19. Multiple Sclerosis Image
Figure 20. Type 1 Diabetes Image
Figure 21. Others Image
Figure 22. Global Autoimmune Disease Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 23. Global Autoimmune Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 24. Global Autoimmune Disease Drug Sales Value Share by Application (2021-2032)
Figure 25. Global Autoimmune Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 26. Global Autoimmune Disease Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 27. North America Autoimmune Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 28. North America Autoimmune Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 29. Europe Autoimmune Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 30. Europe Autoimmune Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 31. Asia-Pacific Autoimmune Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 32. Asia-Pacific Autoimmune Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 33. South America Autoimmune Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 34. South America Autoimmune Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 35. Middle East & Africa Autoimmune Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 36. Middle East & Africa Autoimmune Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 37. USA Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 38. USA Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 39. USA Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 40. Canada Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 41. Canada Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 42. Canada Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 43. Mexico Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 44. Mexico Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 45. Mexico Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 46. Germany Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 47. Germany Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 48. Germany Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 49. France Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 50. France Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 51. France Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 52. U.K. Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 53. U.K. Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 54. U.K. Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 55. Italy Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 56. Italy Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 57. Italy Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 58. Spain Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 59. Spain Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 60. Spain Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 61. Russia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 62. Russia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 63. Russia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 64. Netherlands Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 65. Netherlands Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 66. Netherlands Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 67. Nordic Countries Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 68. Nordic Countries Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 69. Nordic Countries Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 70. China Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 71. China Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 72. China Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 73. Japan Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 74. Japan Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 75. Japan Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 76. South Korea Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 77. South Korea Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 78. South Korea Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 79. India Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 80. India Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 81. India Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 82. Australia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 83. Australia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 84. Australia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 85. Southeast Asia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 86. Southeast Asia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 87. Southeast Asia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 88. Brazil Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 89. Brazil Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 90. Brazil Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 91. Argentina Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 92. Argentina Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 93. Argentina Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 94. Chile Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 95. Chile Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 96. Chile Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 97. Colombia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 98. Colombia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 99. Colombia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 100. Peru Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 101. Peru Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 102. Peru Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 103. Saudi Arabia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 104. Saudi Arabia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 105. Saudi Arabia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 106. Israel Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 107. Israel Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 108. Israel Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 109. UAE Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 110. UAE Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 111. UAE Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 112. Turkey Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 113. Turkey Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 114. Turkey Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 115. Iran Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 116. Iran Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 117. Iran Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 118. Egypt Autoimmune Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 119. Egypt Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 120. Egypt Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 121. Years Considered
Figure 122. Research Process
Figure 123. Key Executives Interviewed
Scope & coverage.
Types
- NSAIDs
- Interferons
- Antihyperglycemics
- Anti-Inflammatory
- Others
Applications
- Psoriasis
- Inflammatory Bowel Disease
- Rheumatoid Arthritis
- Lupus
- Multiple Sclerosis
- Type 1 Diabetes
- Others
Companies covered
- Roche
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Amgen
- AbbVie
- Bristol-Myers Squibb
- Biogen
- AstraZeneca plc
- Abbott Laboratories
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Autoimmune Disease Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Autoimmune Disease Drug Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Autoimmune Disease Drug Market Dynamics
- 2.1 Autoimmune Disease Drug Industry Trends
- 2.2 Autoimmune Disease Drug Industry Drivers
- 2.3 Autoimmune Disease Drug Industry Opportunities and Challenges
- 2.4 Autoimmune Disease Drug Industry Restraints
3 Autoimmune Disease Drug Market by Company
- 3.1 Global Autoimmune Disease Drug Company Revenue Ranking in 2025
- 3.2 Global Autoimmune Disease Drug Revenue by Company (2021-2026)
- 3.3 Global Autoimmune Disease Drug Company Ranking (2024-2026)
- 3.4 Global Autoimmune Disease Drug Company Manufacturing Base and Headquarters
- 3.5 Global Autoimmune Disease Drug Company Product Type and Application
- 3.6 Global Autoimmune Disease Drug Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Autoimmune Disease Drug Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Autoimmune Disease Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Autoimmune Disease Drug Market by Type
- 4.1 Autoimmune Disease Drug Type Introduction
- 4.1.1 NSAIDs
- 4.1.2 Interferons
- 4.1.3 Antihyperglycemics
- 4.1.4 Anti-Inflammatory
- 4.1.5 Others
- 4.2 Global Autoimmune Disease Drug Sales Value by Type
- 4.2.1 Global Autoimmune Disease Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Autoimmune Disease Drug Sales Value by Type (2021-2032)
- 4.2.3 Global Autoimmune Disease Drug Sales Value Share by Type (2021-2032)
5 Autoimmune Disease Drug Market by Application
- 5.1 Autoimmune Disease Drug Application Introduction
- 5.1.1 Psoriasis
- 5.1.2 Inflammatory Bowel Disease
- 5.1.3 Rheumatoid Arthritis
- 5.1.4 Lupus
- 5.1.5 Multiple Sclerosis
- 5.1.6 Type 1 Diabetes
- 5.1.7 Others
- 5.2 Global Autoimmune Disease Drug Sales Value by Application
- 5.2.1 Global Autoimmune Disease Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Autoimmune Disease Drug Sales Value by Application (2021-2032)
- 5.2.3 Global Autoimmune Disease Drug Sales Value Share by Application (2021-2032)
6 Autoimmune Disease Drug Regional Value Analysis
- 6.1 Global Autoimmune Disease Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Autoimmune Disease Drug Sales Value by Region (2021-2032)
- 6.2.1 Global Autoimmune Disease Drug Sales Value by Region: 2021-2026
- 6.2.2 Global Autoimmune Disease Drug Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Autoimmune Disease Drug Sales Value (2021-2032)
- 6.3.2 North America Autoimmune Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Autoimmune Disease Drug Sales Value (2021-2032)
- 6.4.2 Europe Autoimmune Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Autoimmune Disease Drug Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Autoimmune Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Autoimmune Disease Drug Sales Value (2021-2032)
- 6.6.2 South America Autoimmune Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Autoimmune Disease Drug Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Autoimmune Disease Drug Sales Value Share by Country, 2025 VS 2032
7 Autoimmune Disease Drug Country-level Value Analysis
- 7.1 Global Autoimmune Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Autoimmune Disease Drug Sales Value by Country (2021-2032)
- 7.2.1 Global Autoimmune Disease Drug Sales Value by Country (2021-2026)
- 7.2.2 Global Autoimmune Disease Drug Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.7.2 France Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 China Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 India Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Autoimmune Disease Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Autoimmune Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Autoimmune Disease Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Roche
- 8.1.1 Roche Company Information
- 8.1.2 Roche Business Overview
- 8.1.3 Roche Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.1.4 Roche Autoimmune Disease Drug Product Portfolio
- 8.1.5 Roche Recent Developments
- 8.2 Eli Lilly
- 8.2.1 Eli Lilly Company Information
- 8.2.2 Eli Lilly Business Overview
- 8.2.3 Eli Lilly Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.2.4 Eli Lilly Autoimmune Disease Drug Product Portfolio
- 8.2.5 Eli Lilly Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Autoimmune Disease Drug Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 GlaxoSmithKline
- 8.4.1 GlaxoSmithKline Company Information
- 8.4.2 GlaxoSmithKline Business Overview
- 8.4.3 GlaxoSmithKline Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.4.4 GlaxoSmithKline Autoimmune Disease Drug Product Portfolio
- 8.4.5 GlaxoSmithKline Recent Developments
- 8.5 Amgen
- 8.5.1 Amgen Company Information
- 8.5.2 Amgen Business Overview
- 8.5.3 Amgen Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.5.4 Amgen Autoimmune Disease Drug Product Portfolio
- 8.5.5 Amgen Recent Developments
- 8.6 AbbVie
- 8.6.1 AbbVie Company Information
- 8.6.2 AbbVie Business Overview
- 8.6.3 AbbVie Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.6.4 AbbVie Autoimmune Disease Drug Product Portfolio
- 8.6.5 AbbVie Recent Developments
- 8.7 Bristol-Myers Squibb
- 8.7.1 Bristol-Myers Squibb Company Information
- 8.7.2 Bristol-Myers Squibb Business Overview
- 8.7.3 Bristol-Myers Squibb Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.7.4 Bristol-Myers Squibb Autoimmune Disease Drug Product Portfolio
- 8.7.5 Bristol-Myers Squibb Recent Developments
- 8.8 Biogen
- 8.8.1 Biogen Company Information
- 8.8.2 Biogen Business Overview
- 8.8.3 Biogen Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.8.4 Biogen Autoimmune Disease Drug Product Portfolio
- 8.8.5 Biogen Recent Developments
- 8.9 AstraZeneca plc
- 8.9.1 AstraZeneca plc Company Information
- 8.9.2 AstraZeneca plc Business Overview
- 8.9.3 AstraZeneca plc Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.9.4 AstraZeneca plc Autoimmune Disease Drug Product Portfolio
- 8.9.5 AstraZeneca plc Recent Developments
- 8.10 Abbott Laboratories
- 8.10.1 Abbott Laboratories Company Information
- 8.10.2 Abbott Laboratories Business Overview
- 8.10.3 Abbott Laboratories Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
- 8.10.4 Abbott Laboratories Autoimmune Disease Drug Product Portfolio
- 8.10.5 Abbott Laboratories Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst